Momenta

Investor Relations

NASDAQ: MNTA
Price
19.00
Change
+ 1.43
Day High
19.20
Day Low
17.55
Volume
1,859,200
4:00 PM ET on Apr 20, 2015
Stock price graph

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

In July 2010, Momenta’s lead product (developed in collaboration with Sandoz) was approved as the first generic version of Lovenox® (Enoxaparin Sodium Injection). In April 2015, the company announced the FDA approval of once daily Glatopa™ 20 mg/mL (glatiramer acetate injection), a fully substitutable generic version of Copaxone® 20 mg/mL. Glatopa was also developed in collaboration with Sandoz. The company's development pipeline includes a biosimilar version of HUMIRA® (adalimumab) in collaboration with Baxter, a portfolio of other early stage biosimilar programs, necuparanib (formerly M402), a novel oncology drug candidate currently in a Phase 2 trial, and a portfolio of novel autoimmune drug candidates.

View Annual Report and Proxy Material

View all »   RSSRecent Releases

Apr 20, 2015
Momenta Presents Key Glatopa(TM) (glatiramer acetate injection) Data at American Academy of Neurology Annual Meeting

Apr 17, 2015
Momenta Pharmaceuticals Announces Data Presentations on Glatopa(TM) (glatiramer acetate injection) at the American Academy of Neurology's (AAN) 2015 Annual Meeting

Apr 16, 2015
Momenta Pharmaceuticals Announces Conference Call Details Regarding FDA Approval for Glatopa(TM) (glatiramer acetate injection)

View all »Events & Presentations

May 1, 2015 at 10:00 AM ET
Momenta Pharmaceuticals First Quarter 2015 Earnings Call

Lovenox® is a registered trademark of Sanofi-Aventis. Copaxone® is a registered trademark of Teva Pharmaceutical Industries Ltd. Glatopa™ is a trademark of Novartis AG. HUMIRA® is a registered trademark of AbbVie.